Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Development and Validation of a 18F-FDG PET/CT-Based Clinical Prediction Model for Estimating Malignancy in Solid Pulmonary Nodules Based on a Population With High Prevalence of Malignancy.

Guo HY, Lin JT, Huang HH, Gao Y, Yan MR, Sun M, Xu WP, Yan HH, Zhong WZ, Yang XN.

Clin Lung Cancer. 2019 Aug 6. pii: S1525-7304(19)30227-X. doi: 10.1016/j.cllc.2019.07.014. [Epub ahead of print]

PMID:
31474376
2.

Visceral pleural invasion in T1 tumors (≤3 cm), particularly T1a, in the eighth tumor-node-metastasis classification system for non-small cell lung cancer: a population-based study.

Zhang T, Zhang JT, Li WF, Lin JT, Liu SY, Yan HH, Yang JJ, Yang XN, Wu YL, Nie Q, Zhong WZ.

J Thorac Dis. 2019 Jul;11(7):2754-2762. doi: 10.21037/jtd.2019.06.32.

3.

Tacrolimus levels in the prophylaxis of acute graft-versus-host disease in Chinese early after hematopoietic stem cell transplantation.

Tian JX, Zhang P, Miao WJ, Wang XD, Liu XO, Liao YX, Li S, Yan HH.

Ther Drug Monit. 2019 Jun 28. doi: 10.1097/FTD.0000000000000645. [Epub ahead of print]

PMID:
31268965
4.

Label-free gold nanorods sensor array for colorimetric detection and discrimination of biothiols in human urine samples.

Yuan D, Liu JJ, Yan HH, Li CM, Huang CZ, Wang J.

Talanta. 2019 Oct 1;203:220-226. doi: 10.1016/j.talanta.2019.05.076. Epub 2019 May 21.

PMID:
31202329
5.

Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.

Zhong WZ, Chen KN, Chen C, Gu CD, Wang J, Yang XN, Mao WM, Wang Q, Qiao GB, Cheng Y, Xu L, Wang CL, Chen MW, Kang X, Yan W, Yan HH, Liao RQ, Yang JJ, Zhang XC, Zhou Q, Wu YL.

J Clin Oncol. 2019 Sep 1;37(25):2235-2245. doi: 10.1200/JCO.19.00075. Epub 2019 Jun 13.

PMID:
31194613
6.

Breakthrough Moments: Organoid Models of Cancer.

Chan AS, Yan HHN, Leung SY.

Cell Stem Cell. 2019 Jun 6;24(6):839-840. doi: 10.1016/j.stem.2019.05.006.

PMID:
31173712
7.

Establishing Pure Cancer Organoid Cultures: Identification, Selection and Verification of Cancer Phenotypes and Genotypes.

Wallaschek N, Niklas C, Pompaiah M, Wiegering A, Germer CT, Kircher S, Brändlein S, Maurus K, Rosenwald A, Yan HHN, Leung SY, Bartfeld S.

J Mol Biol. 2019 Jul 12;431(15):2884-2893. doi: 10.1016/j.jmb.2019.05.031. Epub 2019 May 29.

PMID:
31150736
8.

Analysis of resistance mechanisms to abivertinib, a third-generation EGFR tyrosine kinase inhibitor, in patients with EGFR T790M-positive non-small cell lung cancer from a phase I trial.

Zhang YC, Chen ZH, Zhang XC, Xu CR, Yan HH, Xie Z, Chuai SK, Ye JY, Han-Zhang H, Zhang Z, Bai XY, Su J, Gan B, Yang JJ, Li WF, Tang W, Luo FR, Xu X, Wu YL, Zhou Q.

EBioMedicine. 2019 May;43:180-187. doi: 10.1016/j.ebiom.2019.04.030. Epub 2019 Apr 23.

9.

A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastases.

Yin K, Li YS, Zheng MM, Jiang BY, Li WF, Yang JJ, Tu HY, Zhou Q, Zhong WZ, Yang XN, Chen HJ, Yan HH, Li LL, Wu YL, Zhang XC.

Lung Cancer. 2019 May;131:134-138. doi: 10.1016/j.lungcan.2019.03.015. Epub 2019 Mar 18.

PMID:
31027690
10.

A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002).

Wang Z, Huang C, Yang JJ, Song Y, Cheng Y, Chen GY, Yan HH, Ben XS, Wang BC, Xu CR, Jiang BY, Zhou Q, Chen HJ, Wu YL.

Eur J Cancer. 2019 Mar;109:183-191. doi: 10.1016/j.ejca.2019.01.007. Epub 2019 Feb 7.

PMID:
30739019
11.

[Clinical application evaluation and revision suggestions of clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for upper respiratory tract infection in children].

Liu QH, Rong P, Wang M, Zhang BL, Xie YM, Zhang JH, Yan HH, Li RB, Li L, Zhang XL, Ma R.

Zhongguo Zhong Yao Za Zhi. 2018 Dec;43(24):4753-4758. doi: 10.19540/j.cnki.cjcmm.20180925.006. Chinese.

PMID:
30717514
12.

An Integrative Data Mining and Omics-Based Translational Model for the Identification and Validation of Oncogenic Biomarkers of Pancreatic Cancer.

Long NP, Jung KH, Anh NH, Yan HH, Nghi TD, Park S, Yoon SJ, Min JE, Kim HM, Lim JH, Kim JM, Lim J, Lee S, Hong SS, Kwon SW.

Cancers (Basel). 2019 Jan 29;11(2). pii: E155. doi: 10.3390/cancers11020155.

13.

Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC.

Zheng MM, Li YS, Jiang BY, Tu HY, Tang WF, Yang JJ, Zhang XC, Ye JY, Yan HH, Su J, Zhou Q, Zhong WZ, Yang XN, Guo WB, Chuai S, Zhang Z, Chen HJ, Wang Z, Liu C, Wu YL.

J Thorac Oncol. 2019 May;14(5):924-932. doi: 10.1016/j.jtho.2019.01.007. Epub 2019 Jan 17.

PMID:
30659989
14.

HS-173 as a novel inducer of RIP3-dependent necroptosis in lung cancer.

Park JH, Jung KH, Kim SJ, Yoon YC, Yan HH, Fang Z, Lee JE, Lim JH, Mah S, Hong S, Kim YS, Hong SS.

Cancer Lett. 2019 Mar 1;444:94-104. doi: 10.1016/j.canlet.2018.12.006. Epub 2018 Dec 21.

PMID:
30583075
15.

The Unique Spatial-Temporal Treatment Failure Patterns of Adjuvant Gefitinib Therapy: A Post Hoc Analysis of the ADJUVANT Trial (CTONG 1104).

Xu ST, Xi JJ, Zhong WZ, Mao WM, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhang YX, Yin JC, Wang Q, Wu YL.

J Thorac Oncol. 2019 Mar;14(3):503-512. doi: 10.1016/j.jtho.2018.11.020. Epub 2018 Dec 3.

PMID:
30521970
16.

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.

Chen RL, Zhao J, Zhang XC, Lou NN, Chen HJ, Yang X, Su J, Xie Z, Zhou Q, Tu HY, Zhong WZ, Yan HH, Guo WB, Wu YL, Yang JJ.

BMC Cancer. 2018 Nov 26;18(1):1171. doi: 10.1186/s12885-018-5078-y.

17.

Chinese nurses are at high risk for suicide: A review of nurses suicide in China 2007-2016.

Zeng HJ, Zhou GY, Yan HH, Yang XH, Jin HM.

Arch Psychiatr Nurs. 2018 Dec;32(6):896-900. doi: 10.1016/j.apnu.2018.07.005. Epub 2018 Jul 17. Review.

PMID:
30454635
18.

Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer.

Liu SY, Dong ZY, Wu SP, Xie Z, Yan LX, Li YF, Yan HH, Su J, Yang JJ, Zhou Q, Zhong WZ, Tu HY, Yang XN, Zhang XC, Wu YL.

Lung Cancer. 2018 Nov;125:86-92. doi: 10.1016/j.lungcan.2018.09.010. Epub 2018 Sep 14.

PMID:
30429043
19.

A Comprehensive Human Gastric Cancer Organoid Biobank Captures Tumor Subtype Heterogeneity and Enables Therapeutic Screening.

Yan HHN, Siu HC, Law S, Ho SL, Yue SSK, Tsui WY, Chan D, Chan AS, Ma S, Lam KO, Bartfeld S, Man AHY, Lee BCH, Chan ASY, Wong JWH, Cheng PSW, Chan AKW, Zhang J, Shi J, Fan X, Kwong DLW, Mak TW, Yuen ST, Clevers H, Leung SY.

Cell Stem Cell. 2018 Dec 6;23(6):882-897.e11. doi: 10.1016/j.stem.2018.09.016. Epub 2018 Oct 18.

PMID:
30344100
20.

PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation.

Chan LH, Zhou L, Ng KY, Wong TL, Lee TK, Sharma R, Loong JH, Ching YP, Yuan YF, Xie D, Lo CM, Man K, Artegiani B, Clevers H, Yan HH, Leung SY, Richard S, Guan XY, Huen MSY, Ma S.

Cell Rep. 2018 Oct 16;25(3):690-701.e8. doi: 10.1016/j.celrep.2018.09.053.

21.

KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.

Kang YW, Lee JE, Jung KH, Son MK, Shin SM, Kim SJ, Fang Z, Yan HH, Park JH, Han B, Cheon MJ, Woo MG, Lim JH, Kim YS, Hong SS.

Cancer Lett. 2018 Dec 1;438:174-186. doi: 10.1016/j.canlet.2018.09.013. Epub 2018 Sep 11.

PMID:
30217561
22.

Impact of menopausal status and HER-2/neu protein on efficacy of EGFR-TKI in EGFR mutant patients with non-small cell lung cancer.

Yin ZJ, Tu HY, Fu M, Zhong WZ, An SJ, Yan HH, Chen HJ, Lin HR, Wu YL.

J Cancer. 2018 Jul 30;9(17):2987-2993. doi: 10.7150/jca.25679. eCollection 2018.

23.

Prophylactic air-extraction strategy after thoracoscopic wedge resection.

Zhang JT, Tang YC, Lin JT, Dong S, Nie Q, Jiang BY, Yan HH, Wen ZW, Wu Y, Yang XN, Wu YL, Zhong WZ.

Thorac Cancer. 2018 Nov;9(11):1406-1412. doi: 10.1111/1759-7714.12850. Epub 2018 Sep 6.

24.

Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway.

Fang Z, Jung KH, Yan HH, Kim SJ, Rumman M, Park JH, Han B, Lee JE, Kang YW, Lim JH, Hong SS.

Cell Physiol Biochem. 2018;47(5):1751-1768. doi: 10.1159/000491058. Epub 2018 Jun 28.

25.

Artemisia Capillaris leaves inhibit cell proliferation and induce apoptosis in hepatocellular carcinoma.

Kim J, Jung KH, Yan HH, Cheon MJ, Kang S, Jin X, Park S, Oh MS, Hong SS.

BMC Complement Altern Med. 2018 May 8;18(1):147. doi: 10.1186/s12906-018-2217-6.

26.

EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: Analysis based on large-scale data from China.

Pi C, Xu CR, Zhang MF, Peng XX, Wei XW, Gao X, Yan HH, Zhou Q.

Thorac Cancer. 2018 Jul;9(7):814-819. doi: 10.1111/1759-7714.12651. Epub 2018 May 2.

27.

A novel tropomyosin-related kinase A inhibitor, KK5101 to treat pancreatic cancer.

Fang Z, Han B, Jung KH, Lee JH, El-Damasy AK, Gadhe CG, Kim SJ, Yan HH, Park JH, Lee JE, Kang YW, Pae AN, Keum G, Hong SS.

Cancer Lett. 2018 Jul 10;426:25-36. doi: 10.1016/j.canlet.2018.03.041. Epub 2018 Mar 30.

PMID:
29605512
28.

Radiosensitization of the PI3K inhibitor HS-173 through reduction of DNA damage repair in pancreatic cancer.

Park JH, Jung KH, Kim SJ, Fang Z, Yan HH, Son MK, Kim J, Kang YW, Lee JE, Han B, Lim JH, Hong SS.

Oncotarget. 2017 Dec 1;8(68):112893-112906. doi: 10.18632/oncotarget.22850. eCollection 2017 Dec 22.

29.

Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.

Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, Zhong WZ, Tu HY, Chen HJ, Wang Z, Xu CR, Wang BC, Du HJ, Chuai S, Han-Zhang H, Su J, Zhou Q, Yang XN, Guo WB, Yan HH, Liu YH, Yan LX, Huang B, Zheng MM, Wu YL.

Ann Oncol. 2018 Apr 1;29(4):945-952. doi: 10.1093/annonc/mdy009.

PMID:
29346604
30.

Systematic assessment of cervical cancer initiation and progression uncovers genetic panels for deep learning-based early diagnosis and proposes novel diagnostic and prognostic biomarkers.

Long NP, Jung KH, Yoon SJ, Anh NH, Nghi TD, Kang YP, Yan HH, Min JE, Hong SS, Kwon SW.

Oncotarget. 2017 Nov 25;8(65):109436-109456. doi: 10.18632/oncotarget.22689. eCollection 2017 Dec 12.

31.

Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators.

Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.

PMID:
29174310
32.

A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.

Tu HY, Ke EE, Yang JJ, Sun YL, Yan HH, Zheng MY, Bai XY, Wang Z, Su J, Chen ZH, Zhang XC, Dong ZY, Wu SP, Jiang BY, Chen HJ, Wang BC, Xu CR, Zhou Q, Mei P, Luo DL, Zhong WZ, Yang XN, Wu YL.

Lung Cancer. 2017 Dec;114:96-102. doi: 10.1016/j.lungcan.2017.11.005. Epub 2017 Nov 7. Review.

PMID:
29173773
33.

Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus.

Zhou J, Li C, Zhao G, Chu H, Wang D, Yan HH, Poon VK, Wen L, Wong BH, Zhao X, Chiu MC, Yang D, Wang Y, Au-Yeung RKH, Chan IH, Sun S, Chan JF, To KK, Memish ZA, Corman VM, Drosten C, Hung IF, Zhou Y, Leung SY, Yuen KY.

Sci Adv. 2017 Nov 15;3(11):eaao4966. doi: 10.1126/sciadv.aao4966. eCollection 2017 Nov.

34.

BRAIN study: it is hard to draw a conclusion - Authors' reply.

Yang JJ, Yan HH, Wu YL.

Lancet Respir Med. 2017 Nov;5(11):e34. doi: 10.1016/S2213-2600(17)30385-5. No abstract available.

PMID:
29115275
35.

[A commentary of literature research of traditional Chinese medicine for acute upper respiratory tract infection in children].

Rong P, Ma R, Liu QH, Yan HH, Hu SY, Li XM, Zhang XL, Zheng WK.

Zhongguo Zhong Yao Za Zhi. 2017 Apr;42(8):1455-1466. doi: 10.19540/j.cnki.cjcmm.2017.0042. Review. Chinese.

PMID:
29071847
36.

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.

Yang JJ, Zhou C, Huang Y, Feng J, Lu S, Song Y, Huang C, Wu G, Zhang L, Cheng Y, Hu C, Chen G, Zhang L, Liu X, Yan HH, Tan FL, Zhong W, Wu YL.

Lancet Respir Med. 2017 Sep;5(9):707-716. doi: 10.1016/S2213-2600(17)30262-X. Epub 2017 Jul 19.

PMID:
28734822
37.

Tumor vessel normalization by the PI3K inhibitor HS-173 enhances drug delivery.

Kim SJ, Jung KH, Son MK, Park JH, Yan HH, Fang Z, Kang YW, Han B, Lim JH, Hong SS.

Cancer Lett. 2017 Sep 10;403:339-353. doi: 10.1016/j.canlet.2017.06.035. Epub 2017 Jul 6.

PMID:
28688971
38.

Corrigendum to "Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer" [Cancer Lett. 396 (2017) 155-166].

Jung KH, Choi IK, Lee HS, Yan HH, Son MK, Ahn HM, Hong J, Yun CO, Hong SS.

Cancer Lett. 2017 Sep 28;404:93. doi: 10.1016/j.canlet.2017.06.019. Epub 2017 Jun 22. No abstract available.

PMID:
28646638
39.

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.

Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH, Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, Zhang YC, Niu FY, Wu YL.

J Thorac Oncol. 2017 Sep;12(9):1368-1375. doi: 10.1016/j.jtho.2017.05.018. Epub 2017 May 30.

40.

Amygdalar Endothelin-1 Regulates Pyramidal Neuron Excitability and Affects Anxiety.

Chen M, Yan HH, Shu S, Pei L, Zang LK, Fu Y, Wang ZF, Wan Q, Bi LL.

Sci Rep. 2017 May 24;7(1):2316. doi: 10.1038/s41598-017-02583-6.

41.

[Long-term outcome of laryngeal framework reconstruction using titanium mesh in glottic cancer after frontolateral vertical partial laryngectomy].

Wu D, Yu JC, Yan HH, Mai JH, Li QL, Li H, Yang AK, Zhang Q, Guo ZM, Liu XK.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2017 Apr 5;31(7):552-555. doi: 10.13201/j.issn.1001-1781.2017.07.015. Chinese. No abstract available.

PMID:
29871309
42.

Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.

Jung KH, Choi IK, Lee HS, Yan HH, Son MK, Ahn HM, Hong J, Yun CO, Hong SS.

Cancer Lett. 2017 Jun 28;396:155-166. doi: 10.1016/j.canlet.2017.03.009. Epub 2017 Mar 15. Erratum in: Cancer Lett. 2017 Sep 28;404:93.

PMID:
28315430
43.

Hippocampal Endothelin-1 decreases excitability of pyramidal neurons and produces anxiolytic effects.

Chen M, Shu S, Yan HH, Pei L, Wang ZF, Wan Q, Bi LL.

Neuropharmacology. 2017 May 15;118:242-250. doi: 10.1016/j.neuropharm.2017.03.014. Epub 2017 Mar 14.

PMID:
28302570
44.

Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer.

Dong ZY, Zhai HR, Hou QY, Su J, Liu SY, Yan HH, Li YS, Chen ZY, Zhong WZ, Wu YL.

Oncologist. 2017 Jan;22(1):61-69. doi: 10.1634/theoncologist.2016-0150.

45.

A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.

Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY, Wang Z, Xu CR, Su J, Wang BC, Jiang BY, Bai XY, Zhong WZ, Yang XN, Wu YL.

Br J Cancer. 2017 Feb 28;116(5):568-574. doi: 10.1038/bjc.2016.456. Epub 2017 Jan 19.

46.

Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study.

Dong S, Zhao N, Deng W, Sun HW, Niu FY, Yang JJ, Zhong WZ, Li F, Yan HH, Xu CR, Zhang QY, Yang XN, Liao RQ, Nie Q, Wu YL.

World J Surg Oncol. 2017 Jan 9;15(1):12. doi: 10.1186/s12957-016-1064-5.

47.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.

Dong ZY, Zhong WZ, Zhang XC, Su J, Xie Z, Liu SY, Tu HY, Chen HJ, Sun YL, Zhou Q, Yang JJ, Yang XN, Lin JX, Yan HH, Zhai HR, Yan LX, Liao RQ, Wu SP, Wu YL.

Clin Cancer Res. 2017 Jun 15;23(12):3012-3024. doi: 10.1158/1078-0432.CCR-16-2554. Epub 2016 Dec 30.

48.

Little Influence of Bevacizumab in Diagnosis of Leptomeningeal Metastases in Current Study.

Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, Yan HH, Wu YL.

J Thorac Oncol. 2017 Jan;12(1):e5-e6. doi: 10.1016/j.jtho.2016.10.004. No abstract available.

49.

[The effect of preoperative induction chemotherapy on long-term survival of patients with advanced squamous cell carcinoma of the oral cavity tongue].

Zhang XR, Yu F, Yan HH, Tan GJ, Zhou YB, Liu XK.

Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2016 Nov 5;30(21):1689-1693. doi: 10.13201/j.issn.1001-1781.2016.21.006. Chinese.

PMID:
29871175
50.

HS-173, a novel PI3K inhibitor suppresses EMT and metastasis in pancreatic cancer.

Rumman M, Jung KH, Fang Z, Yan HH, Son MK, Kim SJ, Kim J, Park JH, Lim JH, Hong S, Hong SS.

Oncotarget. 2016 Nov 22;7(47):78029-78047. doi: 10.18632/oncotarget.12871.

Supplemental Content

Support Center